Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00417261 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of Single and Multiple-Doses of ATF936 and AXT914 Administered Orally in Healthy Subjects.
A Phase 1 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 1
- Development phase
- 65
- Enrollment target
NCT00417261 is a Phase 1 study that has completed, run by Novartis. The registered enrollment target is 65 participants.
The verdict
NCT00417261, a Phase 1 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 65 participants
- Enrollment target
Study Summary
This is a first-in-human study and is designed to evaluate the safety, tolerability, pharmacodynamic and pharmacokinetic effects of a single and multiple-doses of ATF936 and AXT914 administered orally in healthy subjects.
Interventions
- DRUG ATF936
- DRUG AXT914
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2006-11 |
| Est. Completion | 2008-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00417261
The ClinicalTrials.gov registry entry for NCT00417261 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ATF936 is the first listed.
NCT00417261 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00417261 about?
NCT00417261 is a clinical study titled "Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of Single and Multiple-Doses of ATF936 and AXT914 Administered Orally in Healthy Subjects.". This is a first-in-human study and is designed to evaluate the safety, tolerability, pharmacodynamic and pharmacokinetic effects of a single and multiple-doses of ATF936 and AXT914 administered orally in healthy subjects.
What is the current status of trial NCT00417261?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2006-11. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00417261?
The interventions under investigation include: ATF936 (DRUG), AXT914 (DRUG).
Who is sponsoring clinical trial NCT00417261?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.